Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan A, Thangarajah M, An N, Borowski BJ, Reddy AL, Aisen P, Dage JL, Foroud T, Ghetti B, Griffin P, Hammers D, Iaccarino L, Jack CR Jr, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Beckett L, Gao S, Carrillo MC, Rabinovici G, Apostolova LG, Dickerson B, Vemuri P; LEADS Consortium. Eloyan A, et al. Among authors: wolk da. Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S89-S97. doi: 10.1002/alz.13402. Epub 2023 Jul 25. Alzheimers Dement. 2023. PMID: 37491599 Review.
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease.
Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM, Reddin JS, Alavi A, Kimberg DY, Wolk DA, Julin P, Newberg AB, Arnold SE, Detre JA. Musiek ES, et al. Among authors: wolk da. Alzheimers Dement. 2012 Jan;8(1):51-9. doi: 10.1016/j.jalz.2011.06.003. Epub 2011 Oct 21. Alzheimers Dement. 2012. PMID: 22018493 Free PMC article.
Amyloid imaging in dementias with atypical presentation.
Wolk DA, Price JC, Madeira C, Saxton JA, Snitz BE, Lopez OL, Mathis CA, Klunk WE, DeKosky ST. Wolk DA, et al. Alzheimers Dement. 2012 Sep;8(5):389-98. doi: 10.1016/j.jalz.2011.07.003. Epub 2012 Jan 30. Alzheimers Dement. 2012. PMID: 22285638 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative. Caroli A, et al. Neurology. 2015 Feb 3;84(5):508-15. doi: 10.1212/WNL.0000000000001209. Epub 2015 Jan 7. Neurology. 2015. PMID: 25568301 Free PMC article.
324 results